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ABSTRACT
The wobble uridine of certain bacterial and
mitochondrial tRNAs is modified, at position 5,
through an unknown reaction pathway that utilizes
the evolutionarily conserved MnmE and GidA
proteins. The resulting modification (a methyluridine
derivative) plays a critical role in decoding NNG/A
codons and reading frame maintenance during
mRNA translation. The lack of this tRNA modifica-
tion produces a pleiotropic phenotype in bacteria
and has been associated with mitochondrial
encephalomyopathies in humans. In this work, we
use in vitro and in vivo approaches to characterize
the enzymatic pathway controlled by the
Escherichia coli MnmE GidA complex. Surprisingly,
this complex catalyzes two different GTP- and
FAD-dependent reactions, which produce
5-aminomethyluridine and 5-carboxymethylamino-
methyluridine using ammonium and glycine,
respectively, as substrates. In both reactions,
methylene-tetrahydrofolate is the most probable
source to form the C5-methylene moiety, whereas
NADH is dispensable in vitro unless FAD levels are
limiting. Our results allow us to reformulate the bac-
terial MnmE GidA dependent pathway and propose
a novel mechanism for the modification reactions
performed by the MnmE and GidA family proteins.
INTRODUCTION
Transfer RNAs (tRNAs) are by far the most heavily and
diversely modiﬁed of all cellular RNAs (1). Modiﬁcations
are introduced posttranscriptionally by speciﬁc enzymes
and are critical for the ﬁne-tuning of tRNA functions.
Many of these modiﬁcations frequently appear in the
anticodon wobble position (position 34) and are pivotal
in the mRNA decoding process by stabilizing correct
codon–anticodon interactions (1,2). Modiﬁcations at
wobble uridines are classiﬁed into two groups according
to their chemical structures and decoding properties:
5-hydroxyuridine derivatives (xo
5U) with an oxygen
atom directly bonded to the C5 atom of the uracil base,
and 5-methyluridine derivatives (xm
5U) with a methylene
carbon directly bonded to the C5 atom. The last ones are
mostly found in tRNAs that decode two-family box
triplets ending in A or G, and include 2-thiouridine
derivatives (xm
5s
2U) and 20-O-methyluridine derivatives
(xm
5Um). Modiﬁed nucleosides of the xm
5s
2U type
restrict the wobble capacity of uridine because the
thiolation at position 2 of U34 stabilize the C30-endo
puckering conformation of the ribose, which facilitates
the base paring with purines (A or G) and prevents mis-
reading of codons ending in U or C (3). The xm
5 modiﬁ-
cation seems to be critical for decoding NNG/A codons by
stabilizing U G pairing at the wobble position as well as
improving reading of the NNA codons (3–9). The lack of
these modiﬁcations produces translational frameshifting
and a pleiotropic phenotype in bacteria (1), whereas it
has been associated with mitochondrial encephalo-
myopathies in humans (10) and mitochondrial
dysfunction in a human cell line (11). Interestingly, some
proteins involved in the biosynthesis of the xm
5(s
2)U
type nucleosides are evolutionarily conserved from
bacteria to humans, so that the use of Escherichia coli to
ascertain the biochemical and functional roles of such
proteins may guide the study of their eukaryotic
counterparts (11).
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heterotetrameric complex that controls the formation
of 5-carboxymethylaminomethyluridine (cmnm
5U) in
the wobble position of tRNA
Lys
mnm5s2UUU, tRNA
Glu
mnm5s2UUC,
tRNA
Gln
cmnm5s2UUG, tRNA
Leu
cmnm5UmAA, tRNA
Arg
mnm5UCU and
tRNA
Gly
mnm5UCC (Figure 1) (12–14). In certain tRNAs
(tRNA
Lys
mnm5s2UUU,tRNA
Glu
mnm5s2UUC and tRNA
Arg
mnm5UCU), the
cmnm
5 group may be demodiﬁed to 5-aminomethyl
(nm
5) and subsequently methylated in an S-adenosyl-L-
methionine (AdoMet) dependent step to produce
methylaminomethyl (mnm
5). Both reactions are carried
out by the same enzyme called MnmC (13,15,16).
Protein MnmA, together with the cysteine desulfurase
IscS and sulfur transfer mediators TusA-E, is required
for the thiolation at position 2 of the uridine that occurs
in tRNA
Lys
mnm5s2UUU, tRNA
Glu
mnm5s2UUC, tRNA
Gln
cmnm5s2UUG (17,18).
Modiﬁcations at the 2- and 5-positions occur
independently of each other. Meanwhile, the function of
MnmA and MnmC in tRNA modiﬁcation is rather well
understood, the precise role of proteins MnmE and GidA
remains unknown and it is unclear how many steps
precede the formation of the cmnm
5 group (Figure 1).
Results obtained in vivo have shown that both the
MnmE GTPase activity as well as the GidA FAD-
binding activity is necessary for tRNA modiﬁcation
(14,19–21). Biochemical and structural studies indicated
that MnmE binds 50-formyl-tetrahydrofolate, which was
proposed to be the one-carbon group donor in the mod-
iﬁcation reaction (22). Data obtained from mutants where
diﬀerent steps of the tetrahydrofolate (THF) pathway
were interrupted indicated that the C5-methylene moiety
of mnm
5U or cmnm
5U is derived from this pathway,
although apparently not from 5-formyl-THF or methyl-
THF (T. Suzuki and T. Suzuki, 22nd tRNA workshop,
Sweden, 2007). Therefore, the one-carbon group donor
remains uncertain. In contrast, glycine was reported to
be directly incorporated into the cmnm-group of
cmnm
5U in vivo (T. Suzuki and T. Suzuki, 22nd tRNA
workshop, Sweden, 2007). Curiously, taurine (t) is incor-
porated into human mitochondrial tRNA
Lys and
tRNA
Leu(UUR) in place of cmnm (23). This led to the
hypothesis that proteins of the MnmE and GidA
families jointly catalyze the formation of an unknown
intermediate in the modiﬁcation pathway of the wobble
uridine, whereas the subsequent activity of a taurine or
glycine transferase would be responsible for construction
of the tm
5 group in humans, or the cmnm
5 group in yeast
and bacteria (14,23,24; Figure 1). However, there is no
evidence for this independent, second step. For example,
no bacterial or yeast mutants have been isolated where the
putative intermediate produced by the MnmE and GidA
proteins accumulates. Therefore, the possibility that the
complex formed by these proteins drives all the reaction
steps in the cmnm
5/tm
5-side chain synthesis cannot be
ruled out.
In this work, we use both in vitro and in vivo approaches
to characterize the MnmE GidA-dependent pathway.
Our results indicate that the MnmE GidA complex
catalyzes two diﬀerent tRNA modiﬁcation reactions by
which the nm and cmnm groups are incorporated into
position 5 of the wobble uridine, without participation
of any more proteins.
MATERIALS AND METHODS
Bacterial strains, plasmids, growth conditions and
protein techniques
Escherichia coli strains and plasmids used in this study are
listed in Supplementary Table S1. Deletion of the mnmC
and folE genes was performed by targeted homologous
recombination as described (25) using primers shown in
Supplementary Table S2. Deletion of the target gene was
conﬁrmed by PCR. The N-terminal FLAG-tagged mnmC
gene was ampliﬁed by PCR from genomic DNA of
MC1000 E. coli strain using the speciﬁc primers FLAG-
MnmC(F) (GACTATAAAGACGACGACGACAAAA
AACACTACTCCATACAACC, FLAG sequence
underlined) and FLAG-MnmC(R) (TTACCCCGCCTT
AACCGCTTTACCCTTCAAC), and cloned into pBAD
TOPO TA under the ParaC promoter, producing pIC1253.
LBT (Luria–Bertani broth containing 40mg/ml thymine)
and LAT (LBT containing 20g of Difco agar per litre)
were used for routine cultures and plating of E. coli.
When required, antibiotics were added at the following
concentrations: 100mg/ml of ampicillin, 12.5mg/ml of tet-
racycline, and 25mg/ml of kanamycin. Cell growth was
monitored by measuring the optical density (OD) of the
cultures at 600nm. Recombinant proteins were puriﬁed
according to standard procedures. Unless otherwise
speciﬁed, protein MnmE and FLAG-GidA was puriﬁed
from a gidA::Tn10 mutant (strain IC5923) and
mnmE::kan mutant (strain IC5924), respectively.
MnmE GidA heterotetramer formation
To obtain the MnmE GidA heterotetramer, 10mM ﬁnal
concentration of the MnmE and FLAG-GidA proteins
were mixed in 40ml of the following buﬀer: 50mM Tris–
HCl (pH 7.5), 50mM KCl, 10mM magnesium acetate,
5mM DTT, 5mM MgCl2 and 3% glycerol. The mix
was incubated at room temperature (20–22 C) for  2h.
Isothermal titration calorimetry assay
Binding aﬃnity of THF derivatives to MnmE was deter-
mined by isothermal titration calorimetry (ITC) in a
MicroCal VP-ITC isothermal titration calorimeter
(MicroCal, Northampton, MA, USA). Calorimetric
experiments consisted of the titration of a 20–30mM
MnmE solution with a 300–450mM solution of the THF
derivative at 25 C in 50mM Tris–HCl pH 7.5, 100mM
KCl, 5mM MgCl2 and 2mM b-mercaptoethanol. To
obtain the Kd, the data were ﬁtted using software
developed at the BIFI and implemented in Origin 7.0
(OriginLab).
In vitro transcription of E. coli tRNA
Lys
Unmodiﬁed E. coli tRNA
Lys was prepared by in vitro tran-
scription of BstNI-digested plasmid (pUC19-tRNA
Lys, 26)
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Nucleic Acids Research, 2009,Vol.37, No. 21 7179using the Riboprobe T7-transcription kit (PROMEGA).
Each reaction was performed in a ﬁnal volume of 50ml
containing 40mM Tris–HCl buﬀer, pH 7.9, 10mM
MgCl2, 2mM spermidine, 10mM NaCl, 10mM DTT,
50 U of recombinant RNasin ribonuclease inhibitor,
2.5mM each ribonucleotide (or 2.5mM each rATP,
rGTP and rCTP, 0.1mM rUTP and 125mCi [a-
32P]-
rUTP [20mCi/ml, 800mCi/mmol], when radiolabeled
tRNA was required), 2mg of BstNI-digested plasmid,
50U of T7-RNA polymerase and RNase-free water. The
mix was incubated under mild agitation for 3h at 37 C. At
the end of the incubation period, DNA template was
digested by addition of a few units of RNase-free DNase
Q1 followed by an extra incubation at 37 C for 5min.
Finally, 100ml of 0.3M sodium acetate were added to
the tube, and the radiolabeled tRNA was extracted with
an equal volume (150ml) of water-saturated phenol–chlo-
roform–isoamyl alcohol (25:24:1), ethanol-precipitated
and dried. The transcribed tRNA
Lys was resuspended in
RNase-free water and the removal of unincorporated
nucleotides was performed using Micro Bio-Spin 6
Chromatography Columns (Sephadex G25 column,
BioRad).
Isolation of bulk tRNA from E. coli
Bacterial strains were grown in LBT broth at 37 Ct o
about 5 10
8cells/ml. The cells were lysed, and total
RNA was prepared (27), dissolved in R200 buﬀer
(100mM Tris–H3PO4, pH 6.3, 15% ethanol, 200mM
KCl), and applied to a Nucleobond column (AX500)
equilibrated with the same buﬀer. The column was
washed with 6ml of R200 and 2ml of R650 buﬀer
(same as R200 buﬀer except that the KCl concentration
was 650mM). tRNA was eluted with 7ml of buﬀer R650
and precipitated with 0.7 volume of cold isopropanol,
washed twice with 70% ethanol, dried, dissolved in
water and quantiﬁed in a NanoDrop spectrophotometer.
Note that LB broth is deﬁcient in selenium; therefore,
MnmE/GidA-speciﬁc tRNAs isolated from strains
grown in this medium mostly carry sulphur at position 2.
Determination of the MnmE GidA enzymatic activity
To perform the modiﬁcation in vitro of labelled tRNA
Lys
by the E. coli MnmE GidA complex, the following mix
was made, unless otherwise speciﬁed, in 100ml ﬁnal
volume: 30000c.p.m. (counts per minute) of radioactive
tRNA
Lys in Buﬀer A (100mM Tris–HCl pH 8, 100mM
Ammonium acetate, 5mM MgCl2, 5% Glycerol, 5mM
DTT, 0.5mM FAD, 0.5mM NADH, 0.5mM NADPH,
2mM GTP, 1mM methylene-THF and 10mg BSA).
Glycine, alanine and serine were used at 2mM. All
cofactor solutions were freshly prepared just before use
and protected from light. The enzymatic reaction was
started by addition of the puriﬁed enzymes (2mM ﬁnal
concentration, unless otherwise speciﬁed). A blank
without enzymes was always included in each series of
experiments. The reaction mixture was incubated at
37 C for 40min with mild agitation. Then, the
radiolabeled tRNA was phenol extracted, ethanol
precipitated and digested with nuclease P1. The resulting
nucleotides (1ml portions) were analyzed by bidimensional
thin layer chromatography (2D-TLC) on cellulose plates
using isobutyric acid/concentrated ammonia/water
(66:1:33 [v:v:v]) as the ﬁrst dimension solvent (solvent A,
4h), and 100mM sodium phosphate buﬀer, pH 6.8/
(NH4)2SO4/n-propanol (100/60/2, v/w/v) (solvent B, 4h)
or isopropanol/concentrated HCl/water (68/18/14, v/v/v)
(solvent C, 6h 30 min) as the second dimension solvent.
To perform the modiﬁcation in vitro of total tRNA by
MnmE GidA, we used the same procedure as above with
the following modiﬁcations: the reaction mix was
prepared in 200ml of ﬁnal volume and contained 40mg
of total tRNA puriﬁed from strain IC5653 (an mnmE
gidA double mutant). At the end of the reaction, tRNA
was phenol extracted, ethanol precipitated, degraded to
nucleotides with nuclease P1 and, ﬁnally, treated with bac-
terial alkaline phosphatase. The resulting hydrolysate was
analyzed by HPLC using a Develosil C30 column
(250 4.6mm; Phenomenex Ltd). The chromatographic
conditions for gradient elution were essentially as
described earlier (28). Given that total tRNA was
extracted from a strain where the 2-thiouridylase MnmA
protein is active, absorbance could be monitored at
314nm to maximize the detection of thiolated nucleosides.
Determination of the MnmC enzymatic activity
The tRNA previously modiﬁed by MnmE GidA complex
was phenolysed, ethanol precipitated and incubated with
2mM FLAG-MnmC protein in 200ml (total volume) of
MnmC buﬀer {50mM Tris–Cl (pH 8.0), 50mM
Ammonium acetate, 40mM[ methyl-
14C]AdoMet
(60mCi/mmole) or 0.5mM cold SAM, 0.5mM FAD,
5% glycerol}. After 40 min of incubation at 37 C, the
tRNA was recovered by phenolization and ethanol pre-
cipitation, and digested by nuclease P1 (and by E. coli
alkaline phosphatase when appropriated). The resulting
products were analyzed by 2D-TLC on a cellulose plate
(or by reverse-phase HPLC) as described earlier.
RESULTS
Study of the MnmE GidA modiﬁcation activity using
in vitro synthesized tRNA
Lys and TLC analysis
To determine whether the recombinant MnmE GidA
complex displays tRNA modiﬁcation activity, we
developed an in vitro modiﬁcation assay where the inde-
pendent contribution of the MnmE GidA complex and its
putative substrates and cofactors could be assessed.
Basically, the reaction mix contained recombinant
proteins,
32P-labeled tRNA
Lys, GTP, FAD and NADH/
NADPH. In addition, we included methylene-THF as the
ﬁrst-choice carbon donor because its aﬃnity for MnmE,
while similar to that of the remaining THF derivatives
(Kd 1mM) as determined by ITC, displays a slightly
more favourable enthalpy, suggestive of a better interac-
tion (Table 1). After incubation of the reaction mix, the
tRNA was hydrolyzed by nuclease P1 and analyzed by
2D-TLC. Figure 2 shows that a major spot corresponding
to nucleotide pU was obtained in the absence of any
7180 Nucleic Acids Research, 2009,Vol.37, No. 21protein (panels A1 and B1), and that one additional
compound (C1) appeared after addition of either MnmE
or FLAG-GidA (Figure 2, panels A2 and B2).
Interestingly, when the assay was performed in the
presence of the MnmE GidA complex, a new
compound, named C2, was also detected (Figure 2,
panels A3 and B3). Formation of C2, but not C1, was
absolutely dependent on the presence of FAD and GTP
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Figure 2. The complex MnmE GidA catalyzes the formation of two nucleotides, C2 and C3, on in vitro transcribed tRNA
Lys. Autoradiograms of
tRNA hydrolysates resulting from in vitro modiﬁcation reactions performed in buﬀer A in the presence (+) or absence ( ) of the indicated
components. (A and B) Correspond to the autoradiograms of the TLC analysis in solvents A/C and A/B, respectively. Positions of modiﬁed
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Table 1. Aﬃnity of MnmE to THF derivatives as determined by ITC
a
THF derivative Kd (mM) G (Kcal/mol) H (Kcal/mol)  T S (Kcal/mol)
(6S/6R) 5-formyl-THF 0.20  9.1  1.7  7.4
(6S) 5-formyl-THF 0.26  9.0  5.8  3.2
(6R) 10-formyl-THF 1.5  7.9  5.9  2.0
(6S) 5-methyl-THF 1.1  8.1  5.3  2.8
(6R) 5,10-methylene-THF 0.31  8.9  6.8  2.1
(6S) THF 0.34  8.8  6.0  2.8
aData in this table indicate that all derivatives were bound by MnmE in a favorable and spontaneous way (Kd and G values were similar), although
the binding for 10-formyl-THF and methyl-THF was the less favorable. Assuming that either there is no protonation or this is equal for all ligands,
binding of methylene-THF exhibits a slightly more favorable enthalpy than the remainder.
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related to the MnmE GidA pathway.
Next, we analyzed the role of glycine in the in vitro
modiﬁcation reaction. Addition of this amino acid, but
not alanine or serine, led to disappearance of C2 and pro-
duction of a new compound, designated C3 (Figure 2,
panels A4 and B4, and Supplementary Figure S2).
Formation of C3 was also dependent on inclusion of
both GTP and FAD in the reaction mix (Supplementary
Figure S2). According to reference maps (29), C3
corresponds to cmnm
5U5 0-monophosphate (pcmnm
5U),
but C2 cannot be assigned.
MnmC converts nucleotides C2 and C3 (pcmnm
5U) to
mnm
5U5 0-monophosphate (pmnm
5U)
MnmC is a bifunctional enzyme whose C-terminal domain
catalyzes demodiﬁcation of cmnm
5(s
2)U to nm
5(s
2)U,
whereas its N-terminal domain independently methylates
nm
5(s
2)U to form the ﬁnal product mnm
5(s
2)U (16;
Figure 1). Therefore, considering that cmnm
5U and
nm
5U are substrates for MnmC, we decided to use this
enzyme to investigate the nature of compounds C2 and C3
(pcmnm
5U) generated by the MnmE GidA activity.
tRNA
Lys, previously modiﬁed in vitro by MnmE GidA
(in the presence or not of glycine), was incubated with
protein FLAG-MnmC, in a buﬀer containing FAD and
SAM (Figure 3A). Subsequently, the tRNA was
hydrolyzed using nuclease P1 and the resulting nucleotides
were analyzed by TLC. Interestingly, C2 and most of C3
(pcmnm
5U) disappeared, whereas two new compounds
migrating as pmnm
5U (C4) and pm
5U (C5), according
to previous chromatographic diagrams (29), were
generated (Figure 3A, compare panels 2 and 3 with 4
and 5, respectively). Synthesis of m
5U could be explained
if our MnmC preparation contained traces of TrmA,
which catalyzes the SAM-dependent methylation of the
uracil in position 54 in all E. coli tRNAs. Note that the
MnmE GidA complex
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Figure 3. MnmC converts C2 and C3 to C4 (mnm
5U5 0-monophosphate, pmnm
5U). 2D-TLC autoradiograms of tRNA hydrolysates resulting from
in vitro modiﬁcation reactions. Solvent system A/C was used for the TLC analysis. (A)[ a-
32P]-UTP-labelled in vitro transcribed tRNA
Lys was
incubated in buﬀer A (A1), modiﬁed by the addition of MnmE GidA to form C2 (pnm
5U) in the absence of glycine (A2), or C3 (pcmnm
5U) in the
presence of this amino acid (A3). C2 and C3 were converted to compound C4 (pmnm
5U) by MnmC (A4 and A5)( B) Cold in vitro transcribed E. coli
tRNA
Lys was incubated in buﬀer A with 40mM[ methyl-
14C]AdoMet (B1). Addition of MnmE GidA (in the absence of glycine) produces C2
(pnm
5U), which is not visible in this step because both the tRNA
Lys as well as the methyl group added to U34 are not radiolabeled (B2).
Incubation of the resulting tRNA with MnmC, FAD and [methyl-
14C]AdoMet produces pmnm
5U( B3). (C and D) Total tRNA from an mnmE
gidA mutant or a wild-type strain, respectively, were treated as in (B), and the products resulting from the MnmC activity are shown.
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is already present in other chromatograms, with variable
relative intensity. Thus, we think it is a product of either
an unusual cleavage or tRNA degradation.
Conversion of C3 to pmnm
5U (C4) by MnmC
(Figure 3A, panels 3 and 5) is in agreement with our pre-
diction that C3 is pcmnm
5U. Conversion of C2 to
pmnm
5U (C4) (Figure 3A, panels 2 and 4) suggests that
C2 is pnm
5U since it works as a substrate for MnmC but
does not exhibit the chromatographic mobility of
pcmnm
5U. If so, this is surprising because it has never
before been reported that nm
5U may be a direct product
of the MnmE GidA complex activity.
To further explore the capability of MnmC to work on
the C2 nucleotide produced by MnmE GidA, we pro-
ceeded as follows (Figure 3B). Five micrograms of
unlabeled in vitro transcribed tRNA
Lys were incubated in
buﬀer A with MnmE GidA and [methyl-
14C]AdoMet, in
the absence of glycine, to form C2 (pnm
5U), according to
our previous results (Figure 3A, panel 2). In this case,
production of pnm
5U could not be detected (Figure 3B,
panel 2) because the in vitro transcribed tRNA used as
substrate was unlabelled, and [methyl-
14C]AdoMet does
not work as a methyl donor in the formation of nm
5U
by MnmE GidA. Then, the tRNA modiﬁed by the
MnmE GidA complex was incubated with MnmC,
FAD and [methyl-
14C]AdoMet, hydrolyzed and analyzed
by TLC. As shown in Figure 3B, panel 3, a radioactive
compound whose migration characteristics correspond to
those of pmnm
5U could be detected. Moreover, 15mgo f
total tRNA isolated from either an mnmE gidA double
mutant (strain IC5653; Figure 3C) or a wild-type strain
(MG1655; Figure 3D) were treated in the same way
as in Figure 3B. Addition of MnmC, FAD, and
14C-radiolabeled SAM to total tRNA previously
modiﬁed in vitro by the MnmE GidA complex (in the
absence of glycine, i.e. under conditions where only the
nucleotide corresponding to C2, pnm
5U, is formed)
produced compounds whose migration characteristics
are those of pmnm
5U and pmnm
5s
2U (Figure 3C and
D). The tRNAs isolated from the wild-type strain that
are substrates for MnmE GidA/MnmC are mostly
modiﬁed, which may explain the less amount of labeled
products obtained in this case (compare Figure 3C and
D). Altogether these experiments support that MnmC
transforms nucleotide C2 (pnm
5U), produced by
MnmE GidA in the absence of glycine, to pmnm
5U.
Ammonium ion or glycine may be used by the MnmE GidA
complex to synthesize nm
5U or cmnm
5U, respectively
If compound C2 is pnm
5U, we wondered whether
ammonium is the source of its amine group, given that
the nucleotide is synthesized in the absence of glycine.
Figure 4 shows that removal of ammonium acetate from
the reaction buﬀer prevents formation of C2 (compare
panels B and C). It is important to note that stimulation
of the MnmE GTPase activity (which is essential for the
modifying function of this protein; 20) requires potassium
or ammonium ions (30). In the in vitro modiﬁcation
reaction, potassium ions are present, at least, 10mM due
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Figure 4. Ammonium ion is indispensable to form C2 (pnm
5U) but not
C3 (pcmnm
5U). 2D-TLC autoradiograms of tRNA hydrolysates
resulting from in vitro modiﬁcation reactions performed in buﬀer C
(same as buﬀer A, but without ammonium acetate) supplemented
(+) or not ( ) with the indicated components. Salts were added to
buﬀer C at 100mM, but note that potassium ions are always present at,
at least, 10mM after the addition of the MnmE GidA complex.
Solvent system A/C was used for the TLC analysis.
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mation is carried out in a buﬀer containing 50mM KCl).
This concentration might be suboptimal for eﬃcient stim-
ulation of the MnmE GTPase activity (31), explaining that
elimination of ammonium from the reaction mix impairs
the in vitro tRNA modiﬁcation reaction. However, when
ammonium acetate was substituted by potassium acetate,
the modiﬁcation reaction does not work either, given that
C2 (pnm
5U) is not produced (Figure 4D). The same result
was obtained when sodium acetate was the substituent
(Figure 4E). Interestingly, when ammonium ions are
removed but glycine is added, C3 (pcmnm
5U), but not
C2 (pnm
5U), is formed (Figure 4F). Considering that
the synthesis of both nucleotides requires the presence of
GTP (Supplementary Figures S1 and S2), we conclude
that 10mM KCl is enough to stimulate the MnmE
activity and that ammonium may be used by the
MnmE GidA complex to synthesize the nm
5 group.
Moreover, given that C3 (pcmnm
5U) may be obtained
when glycine, but not ammonium, is present in the
buﬀer (Figure 4F), we propose that C2 (pnm
5U) is not
an intermediate in the C3 (pcmnm
5U) formation and
that synthesis of both compounds is mediated by
MnmE GidA through diﬀerent and independent
pathways (Figure 5). Strikingly, only compound C3
(pcmnm
5U) is produced when ammonium and glycine
are simultaneously present in the reaction mix (Figure 2,
panels A4 and B4). Therefore, we think that the glycine-
dependent reaction is competitively more eﬀective under
the conditions used in these assays.
Reverse-phase HPLC analysis of total E. coli tRNA
modiﬁed in vitro by the MnmE GidA complex
To conﬁrm the TLC data and further investigate how
proteins MnmE, GidA and MnmC work, we performed
the in vitro modiﬁcation assay using total tRNA puriﬁed
from a double mutant mnmE gidA instead of the in vitro
transcribed tRNA
Lys. In this case, the resulting tRNA was
analyzed, after digestion with nuclease P1 and alkaline
phosphatase, by HPLC, using some puriﬁed nucleosides
as controls (Figure 6A). Previous HPLC analysis of tRNA
puriﬁed from null mnmE or gidA mutants (where protein
MnmA is active) revealed accumulation of s
2U and dis-
appearance of mnm
5s
2U in the corresponding
chromatograms (14). In this work, we observed that s
2U
remained accumulated after performing the in vitro mod-
iﬁcation reaction in the absence of the MnmE GidA
complex (Figure 6B). However, when this complex was
added to a reaction mix containing ammonium but not
glycine, s
2U was converted into nm
5s
2U (Figure 6C).
Note that ammonium was indispensable for this conver-
sion since s
2U remained accumulated in the absence of the
cation (Figure 6D). Moreover, when the reaction mix
contained glycine but not ammonium, s
2U was partially
converted into cmnm
5s
2U, whereas no production of
nm
5s
2U was observed (Figure 6E). Altogether these
results support the idea that the MnmE GidA complex
catalyzes the in vitro biosynthesis of nm
5s
2U and
cmnm
5s
2Ui nE. coli tRNA through two independent
reactions and without participation of other proteins.
Curiously, both cmnm
5s
2U and nm
5s
2U were detected
after the simultaneous addition of ammonium and
glycine to the reaction mix (Figure 6F). This result
diﬀers from that obtained when the MnmE GidA
complex activity was analyzed using in vitro
synthesized tRNA
Lys and TLC. In such a case,
pcmnm
5U was the only product detected when both
ammonium and glycine were included in the reaction
(compound C3 in Figure 2, panels A4 and B4), in
spite of we detected formation of pnm
5U (C2) if only
ammonium was present (Figure 2, panels A3 and B3).
Thus, it seems that the glycine-dependent reaction
is competitively more eﬀective when the in vitro
synthesized tRNA
Lys is the substrate. Considering that
this tRNA is completely unmodiﬁed, in contrast to
the total tRNA puriﬁed from the mnmE gidA strain
(Figure 6), it is tempting to speculate that some tRNA
modiﬁcation(s) outside the 5-position of U34 modulate
the eﬃciency of the reactions mediated by the
MnmE GidA complex.
To ﬁrmly establish the identities of the nucleosides
resulting from the in vitro MnmE GidA activity, we
again analyzed their ability to be used as substrates by
the bifunctional enzyme MnmC. As expected, MnmC con-
verted the peaks assigned to nm
5s
2U and cmnm
5s
2U into
mnm
5s
2U (Supplementary Figure S3, compare panels B
and D with C and E, respectively).
To further demonstrate that nm
5U is not an intermedi-
ate in the synthesis of cmnm
5U mediated by
MnmE GidA, the bulk tRNA puriﬁed from an mnmC2
mutant (where nm
5s
2U accumulates) was used as substrate
for an in vitro modiﬁcation reaction mediated by
MnmE GidA in the presence of glycine (with or without
ammonium) and, as expected, no conversion of nm
5s
2Ut o
cmnm
5s
2U was observed (Supplementary Figure S4). In
addition, we used total tRNA extracted from an mnmE
gidA mutant as substrate in a reaction catalyzed by
MnmE GidA in the presence of ammonium (Figure 7).
After phenol extraction and ethanol precipitation, the
resulting tRNA, which carried nm
5s
2U (Figure 7B), was
mixed with MnmE GidA and glycine (in the presence or
absence of ammonium). The HPLC pattern of the tRNA
remained unaltered after this second reaction (Figure 7C),
supporting that nm
5s
2U is not a substrate for
MnmE GidA.
Finally, we thought that if the MnmE GidA activity is
able to introduce the nm
5 group at the wobble uridine,
the modiﬁed nucleoside should be found in the tRNA
isolated from a null mnmC mutant. As expected, HPLC
analysis of tRNA from an mnmC::kan strain revealed
the presence of nm
5s
2U, in addition to cmnm
5s
2U, in
the hydrolysates (Figure 6G). Curiously, this nucleoside
was previously not identiﬁed in tRNA from an mnmC1
mutant (13), which we now know carries a nonsense
mutation in the mnmC gene. Here, we have carefully
analyzed the tRNA extracted from mutant mnmC1 and
detected the presence of nm
5s
2U (Figure 6H). Whether
such a discrepancy may be due to the diﬀerent growth
medium used in each case is a question that remains to
be explored.
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Nucleic Acids Research, 2009,Vol.37, No. 21 7185Involvement of FAD and NADH in the tRNA
modiﬁcation reaction
Mutations aﬀecting the FAD-binding domain of GidA
impair tRNA modiﬁcation in vivo (14, 21). Here, we
have shown that FAD is essential for the in vitro
modiﬁcation reaction (Supplementary Figures S1 and
S2). It was previously postulated that GidA-bound
reduced FAD is required for the last step in the synthesis
of the cmnm
5-group, and that GidA-bound FAD receives
its electrons from NADH, given that GidA binds NADH
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2U nucleoside is not an intermediate in the biosynthetic pathway of cmnm
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(A) was incubated with MnmE GidA in buﬀer A to form nm
5s
2U( B). After phenol extraction and ethanol precipitation, the resulting tRNA was
incubated with MnmE GidA and glycine in buﬀer A, with or without ammonium acetate (C).
Nucleic Acids Research, 2009,Vol.37, No. 21 7187but not NADPH (22,32). Curiously, we have found that
NADH (or NADPH) does not seem to be necessary for
the synthesis in vitro of nm
5s
2U and cmnm
5s
2U if FAD is
present at a high concentration (1 mM) (Figure 8A and B).
Note that appropriate control experiments indicate that
nm
5s
2U and cmnm
5s
2U do not accumulate if FAD is
removed, though NADH or NADPH remains in the
reaction mix. Synthesis of nm
5s
2U and cmnm
5s
2U is dras-
tically reduced when FAD is used at 2mM (Figure 8C and
D). However, under such conditions, the addition of
NADH (but not NADPH) at 0.5mM substantially
improves the nm
5s
2U and cmnm
5s
2U synthesis, mainly
of the last one (Figure 8C and D). These results suggest
that NADH may play a critical role in tRNA modiﬁcation
depending on cell FAD concentrations.
Curiously, it has been reported that TrmFO, a GidA
paralogue involved in the FAD-, NADPH- and
methylene-THF-dependent methylation of uridine at
position 54 of tRNAs, is able to catalyze the in vitro mod-
iﬁcation reaction in the absence of NADPH (33). Given
that NADPH is thought to be required for FAD reduc-
tion, the mentioned ﬁnding was attributed to
copuriﬁcation of the enzyme with the oxidized and
reduced forms of ﬂavin. In this respect, it should be men-
tioned that we have used dialyzed proteins to perform the
experiments shown in Figure 8. Considering the relatively
low aﬃnity of GidA for FAD (Kd 3mM; our own
unpublished results) and NADH (Kd 11mM; 32), we
ﬁnd it unlikely that the dialyzed GidA protein used in
our experiments carried these cofactors.
MnmE GidA uses methylene-THF to form the
C5-methylene moiety of nm
5U and cmnm
5U
While studying the requirements for the in vitro synthesis
of nm
5U by MnmE GidA, we observed that removal of
methylene-THF from the reaction mix did not aﬀect the
accumulation of the modiﬁed nucleoside. This suggests
that MnmE copuriﬁes with the one-carbon unit donor, a
behavior that has also been observed for TrmFO (34,35).
To overcome this diﬃculty and further investigate the
carbon donor used by MnmE GidA, we ﬁrst constructed
a folE::cat mutant. folE encodes GTP cyclohydrolase I,
which is the ﬁrst enzyme of the de novo THF pathway (36).
HPLC analysis of tRNAs puriﬁed from the folE::cat
mutant revealed the disappearance of nucleoside
mnm
5s
2U and accumulation of s
2U, in relation to the
wild-type strain (Table 2). This ﬁnding supports that
THF works as the one-carbon unit donor in the
MnmE GidA modiﬁcation pathway. Then, strain
folE::cat was independently transformed with plasmids
expressing proteins GST-MnmE and FLAG-GidA with
the aim to purify both proteins from cells where THF is
presumably very limited, since only some folate-related
salvage pathway may be active (36). Finally, an in vitro
modiﬁcation assay was performed with bulk tRNA
extracted from an mnmE gidA double mutant and
proteins puriﬁed from the folE::cat strain. The relative
accumulation of nm
5s
2U and s
2U observed under diﬀerent
concentrations of the MnmE GidA complex and folate
derivatives is shown in Table 3. Curiously, when no
external source of folate is included in the reaction mix
(see entry ‘Proteins/No folates’ in Table 3), nm
5s
2U still
accumulates if the MnmE GidA complex is added to
2mM (Table 3, column A). This suggests that the
amount of protein MnmE that is added to the mix still
provides a concentration of the one-carbon unit donor
that is enough to lead the in vitro modiﬁcation of tRNA.
Accordingly, when the concentration of MnmE GidA in
the mix is reduced from 2 to 0.35mM (Table 3, column B),
no signiﬁcant conversion of s
2Ut on m
5s
2U is observed in
the absence of exogenous folate. Moreover, if under such
conditions, the folate derivative is added to 50mM, major
increases of nm
5s
2U are only seen with methylene-THF,
THF or methyl-THF. These results help us to discard
5-formyl-, 10-formyl- and methenyl-THF as the one-
carbon unit donor. However, given that no one-carbon
unit is carried by THF, it is possible that our preparation
of this compound contained traces of the true one-carbon
unit donor, which may be methylene-THF or methyl-
THF. We assume that traces of one of them are also
present in the other one, explaining that the in vitro
reaction works with both substrates. The use of the
folate derivative at 1mM (Table 3, column C) still led to
the production of nm
5s
2U in the case of THF, methylene-
THF and methyl-THF, with methylene-THF appearing
to be slightly more eﬀective. A further decrease in the
concentration of these derivatives did not lead to conclu-
sive results since the eﬃciency of the reaction was drasti-
cally reduced (data not shown), probably because the
aﬃnity of MnmE for them is in the low micromolar
range (Table 1).
glyA and metF mutations block the synthesis of
5-formyl-THF and methyl-THF, respectively.
Considering that the in vivo
13C incorporation from
glycine to mnm
5s
2U takes place in glyA and metF
mutants similarly to the wild-type strain, it was suggested
that 5-formyl-THF and methyl-THF are not the direct
substrates to form the C5-methylene moiety of mnm
5s
2U
(T. Suzuki and T. Suzuki, 22nd tRNA workshop, Sweden,
2007). We have veriﬁed such a proposal, ﬁnding that
mnm
5s
2U accumulates in glyA and metF null mutants at
the wild-type level (Table 2). These results, together with
those shown in Table 3, prompt us to conclude that
methylene-THF is the one-carbon unit donor in the mod-
iﬁcation reaction catalyzed by MnmE GidA. If so, data
from Table 3 also suggest that there is no substrate inhi-
bition with THF and methyl-THF since nm
5s
2U
accumulates even when both compounds are added at
1mM (ﬁnal concentration) and, according to our hypoth-
esis, methylene-THF should be a minor contaminant in
the respective preparations. This behaviour is diﬀerent
from that described for TrmFO, whose methylene-
THF-dependent activity is inhibited by concentrations of
THF higher than 2mM (33). Given that the aﬃnity
of MnmE for all THF derivatives tested is similar
(Table 1), we think that either the binding to methylene-
THF is kinetically favored or the aﬃnity for this deriva-
tive signiﬁcantly increases when MnmE is bound to its
partners.
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To characterize the enzymatic pathway of mnm
5U biosyn-
thesis in E. coli, we have puriﬁed proteins MnmE, GidA
and MnmC and checked their ability to modify tRNA
in vitro. Our results show, for the ﬁrst time, that the
MnmE GidA complex catalyses the synthesis of nm
5U
and cmnm
5U in tRNA through two independent reactions
(Figures 3A and 6), in which ammonium and glycine are
the source of the amino and carboxymethylamino moiety,
respectively (Figure 5). The identity of the nucleosides
synthesized by the MnmE GidA complex in vitro (nm
5U
and cmnm
5U) was conﬁrmed by the fact that, in a buﬀer
containing FAD and SAM, they were transformed to
mnm
5U by a recombinant MnmC protein (Figure 3 and
Supplementary Figure S3). In vivo results also indicated
that nm
5U is a direct product of the MnmE GidA activity
because a peak corresponding to this nucleoside could be
clearly identiﬁed in the HPLC analysis of total tRNA
extracted from an mnmC mutant (Figure 6G and H).
It should be emphasized that nm
5U is a ﬁnal product,
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Figure 8. NADH is dispensable for in vitro tRNA modiﬁcation unless FAD levels are limiting. The eﬀect of FAD, NADH and NADPH on the
nm
5s
2U and cmnm
5s
2U formation, in bulk tRNA puriﬁed from a double mnmE gidA mutant, was monitored by HPLC analysis. The MnmE and
GidA proteins were previously dialysed against TBS buﬀer (50mM Tris–HCl pH 7.5, 150mM NaCl and 10mM MgCl2). (A and B) Formation of
nm
5s
2U (ammonium acetate, but not glycine, is present in the reaction mix) and cmnm
5s
2U (glycine, but not ammonium acetate, is present in the
mix), respectively, when FAD (1mM) was added in the absence of exogenous NADH and NADPH (thin line) and when NADH or NADPH was
added at 0.5mM in the absence of FAD (bold line). (C and D) Formation of nm
5s
2U and cmnm
5s
2U, respectively, when FAD is added to 2mM, in
the absence of NADH and NADPH (bold line), or in the presence of NADH (0.5mM, thin line). NADPH (0.5mM) did not improve the production
of nm
5s
2U and cmnm
5s
2U when FAD was used at 2mM (data not shown).
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since it is not a substrate for this complex both in vitro
(Figure 7 and Supplementary Figure S4) as well as in vivo
(Figure 6G and H; note in these panels that nm
5U
accumulates in an mnmC mutant where the
MnmE GidA complex is active). Therefore, the pathway
controlled by MnmE and GidA may be reformulated as
shown in Figure 5 and, more schematically, 9A.
We have previously shown that the GTPase activity of
MnmE and the FAD-binding ability of GidA are required
for tRNA modiﬁcation in vivo (14, 19, 20). Here, we dem-
onstrate that the two in vitro reactions catalyzed by
MnmE GidA are GTP- and FAD-dependent
(Supplementary Figures S1 and S2), suggesting that the
synthesis of nm
5U and cmnm
5U share a similar
mechanism.
Biochemical and structural studies previously indicated
that MnmE binds 50-formyl-THF (22). Consequently, a
tRNA modiﬁcation mechanism based on the formyl
transfer onto C5 of the wobble uridine was proposed
(22). However, we have found here that MnmE exhibits
a similar aﬃnity for diﬀerent THF derivatives, including
50-formyl-THF (Table 1), which questions the role of this
compound as the one-carbon unit donor in the modiﬁca-
tion reaction. We have analyzed the nucleoside composi-
tion of tRNA extracted from mutants where the THF
pathway is inactivated at diﬀerent stages. Our data
support the idea that the C5-methylene moiety of
xm
5(s
2)U nucleosides is derived from the THF pathway,
since s
2U accumulates in a folE mutant, although not from
5-formyl- or methyl-THF, since the level of mnm
5s
2
in glyA and metF mutants is similar to that of the
wild-type strain (Table 2). Moreover, we have performed
in vitro modiﬁcation assays in the presence of diﬀerent
THF derivatives (Table 3). Our data indicate that
neither 5-formyl-, 10-formyl- or methenyl-THF is likely
to be the one-carbon unit donor in the modiﬁcation
reaction. Altogether, these results prompt us to conclude
that methylene-THF is the source of the C5 methylene
moiety of nm
5U and cmnm
5U.
We have shown that NADH is dispensable for the in
vitro function of MnmE GidA unless FAD levels are
limiting (Figure 8). This suggests that FAD undergoes
an oxidation-reduction cycle during synthesis of nm
5U
and cmnm
5U (Figure 9B). In such a cycle, FAD receives
electrons from other participant in the reaction and,
subsequently, donates them to some reaction intermediate.
Probably, there is a spontaneous oxidation of the reduced
FAD during the in vitro modiﬁcation that may explain,
together with the low aﬃnity of GidA for FAD
(Kd 3mM, our own unpublished results), the low eﬃ-
ciency of the reaction when FAD is used at 2mM.
Under these circumstances, addition of NADH would
facilitate production of the reduced FAD, improving the
second step of the FAD cycle associated with the reduc-
tion of some reaction intermediate. Based on these
considerations, we propose a novel catalytic mechanism
for the nm
5U and cmnm
5U modiﬁcation process (Figure
9C), where a general acid of MnmE GidA converts the
methylene-THF into a reactive iminium ion (step 1), in
analogy to the reaction catalyzed by thymidylate
synthase (37). This allows the addition of the amine or
carboxymethylamine group to the methylene group at
N5 of THF (step 2). Then, FAD-bound GidA performs
a dehydrogenation reaction (step 3), facilitating the
nucleophilic attack by the C5 atom of U34 (step 4),
which has been activated, again in analogy with the
thymidilate synthase reaction, through the attack at the
C6 position of U34 by a general acid of the MnmE GidA
complex. Later, FADH2 serves as the reducing agent of
the Schiﬀ’s base (step 7). This step is followed by the lib-
eration of the MnmE GidA complex and production of
cmnm
5U and nm
5U. Our model involves that the THF-
binding domain of MnmE and the FAD-binding domain
of GidA should be close to the C5 position of the wobble
Table 3. Synthesis of nm
5s
2U in the presence of diﬀerent THF derivatives
Reaction mix
a A
b B
b C
b
nm
5s
2U/s
4Us
2U/s
4Un m
5s
2U/s
4Us
2U/s
4Un m
5s
2U/s
4Us
2U/s
4U
No proteins/No folates 0.0000 0.0246 0.0000 0.0248 0.0000 0.0244
Proteins/No folates 0.0142 0.0178 0.0003 0.0271 nd nd
Proteins/methylene-THF 0.0459 0.0026 0.0498 0.0069 0.0457 0
Proteins/THF 0.0486 0.0033 0.0465 0.0055 0.0357 0.0072
Proteins/5 formyl-THF 0.003 0.0264 0.001 0.0279 nd nd
Proteins/10 formyl-THF 0.0274 0.0134 0.0033 0.0269 nd nd
Proteins/methyl-THF 0.0503 0.0024 0.0422 0.0063 0.0225 0.0114
Proteins/methenyl-THF 0.0132 0.0222 0.0034 0.0314 nd nd
atRNA puriﬁed from an mnmE gidA double mutant and buﬀer A were used for performing the in vitro modiﬁcation reaction in the presence of the
components speciﬁed in the column. MnmE and GidA were used at a ﬁnal concentration of 2mM (A) and 0.35mM (B and C). Folates were used at a
ﬁnal concentration of 1mM (A), 50mM (B) and 1mM (C).
bThe numbers are calculated as the absorbance of nm
5s
2Uo rs
2U relative to the absorbance of s
4U at 314nm. Bold numbers are used to highlight the
highest values. nd, not done.
Table 2. Levels of mnm
5s
2U and s
2U in mutants of the THF pathway
mnm
5s
2U/s
4U
a s
2U/s
4U
a
BW25113 (wt) 0.047 0.000
folE::cat 0.002 0.024
metF::kan 0.046 0.000
glyA::kan 0.038 0.000
aThe numbers are calculated as the absorbance of mnm
5s
2Uo rs
2U
relative to the absorbance of s
4U at 314nm and represent the mean
values of at least two independent experiments.
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MnmE GidA heterotetramer that are coupled to the
GTPase cycle of MnmE (32) and to the FAD binding of
GidA (our own unpublished results) might help in the
construction of the active center. Further biochemical
and structural studies will be required to clarify the
detailed mechanism of the MnmE GidA-dependent
reactions.
MnmE and GidA, but not MnmC, are conserved
proteins from bacteria to humans. The MnmE and
GidA homologues in yeast (MSS1 and MTO1) and
humans (GTPBP3 and MTO1) are nucleus-encoded
proteins involved in modiﬁcation of mitochondrial
tRNAs (38–41). The lack of MnmC determines that, in
yeast, the ﬁnal product of the MSS1/MTO1 pathway is
cmnm
5U. In humans, taurine is incorporated into tRNAs
in place of glycine, producing tm
5U (23). Both nucleosides
are probably synthesized in mitochondria by the MnmE
and GidA homologues without the participation of other
proteins, through a reaction similar to that described here.
If so, the complex formed by the human homologues
should be able to use taurine in place of glycine.
It should be noted that GTPBP3 largely conserves the
MnmE properties (11,42), which supports our proposal
that the tRNA modiﬁcation reaction catalyzed by the
eukaryotic homologues should be basically similar to
that performed by the E. coli proteins. The presence of
nm
5(s
2)U in mitochondrial tRNA has not been reported
cmnm5(s2)U
mnm5(s2)U
nm5(s2)U
A (s2)U (s2)U
nm5(s2)U
THF, GTP
FAD, glycine
MnmE￿GidA
MnmC1
MnmC2
THF, GTP 
FAD, NH4+ FAD
FADH2
NADH
NAD
FAD
xm5(s2)U
+
B
CH2–THF
NH4+ or
Glycine
C
Figure 9. The MnmE GidA tRNA modiﬁcation pathway. (A) A schematic of the new formulation for the MnmE GidA pathway. (B) Hypothetical
FAD-dependent steps in the MnmE GidA-mediated reaction. (C) The proposal chemical mechanism for the MnmE GidA catalyzed reactions.
Nucleic Acids Research, 2009,Vol.37, No. 21 7191so far. However, in the light of our results, we think this
issue should be further explored.
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